Literature DB >> 12621305

Effect of dopamine loss and the metabolite 3-O-methyl-[18F]fluoro-dopa on the relation between the 18F-fluorodopa tissue input uptake rate constant Kocc and the [18F]fluorodopa plasma input uptake rate constant Ki.

V Sossi1, J E Holden, R de la Fuente-Fernandez, T J Ruth, A J Stoessl.   

Abstract

Parkinson disease is characterized by the loss of dopaminergic neurons, thus decreasing the system's ability to produce and store dopamine (DA). Such ability is often investigated using 18F-fluorodopa (FD) positron emission tomography. A commonly used model to investigate the DA synthesis and storage rate is the modified Patlak graphical approach. This approach allows for both plasma and tissue input functions, yielding the respective uptake rate constants K(i) and K(occ). This method requires the presence of an irreversible compartment and the absence of any nontrapped tracer metabolite. In the case of K(occ), this last assumption is violated by the presence of the FD metabolite 3-O-methyl-[18F]fluoro-dopa (3OMFD), which makes the K(occ) evaluation susceptible to a downward bias. It was found that both K(i) and K(occ) are influenced by DA loss and thus are not pure measures of DA synthesis and storage. In the case of K(occ), the presence of 3OMFD exacerbates the effect of DA egress, thus introducing a disease-dependent bias in the K(occ) determination. These findings imply that K(i) and K(occ) provide different assessments of disease severity and that, as disease progresses, K(i) and especially K(occ) become more related to DA storage capacity and less to the DA synthesis rate.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12621305     DOI: 10.1097/01.WCB.0000050041.22945.3E

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  9 in total

1.  Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model.

Authors:  Tetsuhiro Kikuchi; Asuka Morizane; Daisuke Doi; Hiroaki Magotani; Hirotaka Onoe; Takuya Hayashi; Hiroshi Mizuma; Sayuki Takara; Ryosuke Takahashi; Haruhisa Inoue; Satoshi Morita; Michio Yamamoto; Keisuke Okita; Masato Nakagawa; Malin Parmar; Jun Takahashi
Journal:  Nature       Date:  2017-08-30       Impact factor: 49.962

2.  In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET.

Authors:  Matthew D Walker; Katherine Dinelle; Rick Kornelsen; Siobhan McCormick; Chenoa Mah; James E Holden; Matthew J Farrer; A Jon Stoessl; Vesna Sossi
Journal:  J Cereb Blood Flow Metab       Date:  2012-08-29       Impact factor: 6.200

3.  Dopamine function in cigarette smokers: an [¹⁸F]-DOPA PET study.

Authors:  Michael A P Bloomfield; Fiona Pepper; Alice Egerton; Arsime Demjaha; Gianpaolo Tomasi; Elias Mouchlianitis; Levi Maximen; Mattia Veronese; Federico Turkheimer; Sudhakar Selvaraj; Oliver D Howes
Journal:  Neuropsychopharmacology       Date:  2014-04-10       Impact factor: 7.853

4.  Dopamine Synthesis Capacity is Associated with D2/3 Receptor Binding but Not Dopamine Release.

Authors:  Anne S Berry; Vyoma D Shah; Daniella J Furman; Robert L White; Suzanne L Baker; James P O'Neil; Mustafa Janabi; Mark D'Esposito; William J Jagust
Journal:  Neuropsychopharmacology       Date:  2017-08-17       Impact factor: 7.853

5.  A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein.

Authors:  Kalpana M Merchant; Jesse M Cedarbaum; Patrik Brundin; Kuldip D Dave; Jamie Eberling; Alberto J Espay; Samantha J Hutten; Monica Javidnia; Johan Luthman; Walter Maetzler; Liliana Menalled; Alyssa N Reimer; A Jon Stoessl; David M Weiner
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

6.  Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease.

Authors:  Alan Whone; Matthias Luz; Mihaela Boca; Max Woolley; Lucy Mooney; Sonali Dharia; Jack Broadfoot; David Cronin; Christian Schroers; Neil U Barua; Lara Longpre; C Lynn Barclay; Chris Boiko; Greg A Johnson; H Christian Fibiger; Rob Harrison; Owen Lewis; Gemma Pritchard; Mike Howell; Charlie Irving; David Johnson; Suk Kinch; Christopher Marshall; Andrew D Lawrence; Stephan Blinder; Vesna Sossi; A Jon Stoessl; Paul Skinner; Erich Mohr; Steven S Gill
Journal:  Brain       Date:  2019-03-01       Impact factor: 13.501

7.  Preliminary evidence of increased striatal dopamine in a nonhuman primate model of maternal immune activation.

Authors:  Melissa D Bauman; Tyler A Lesh; Douglas J Rowland; Cynthia M Schumann; Jason Smucny; David L Kukis; Simon R Cherry; A Kimberley McAllister; Cameron S Carter
Journal:  Transl Psychiatry       Date:  2019-04-12       Impact factor: 6.222

8.  Impact of non-uniform attenuation correction in a dynamic [18F]-FDOPA brain PET/MRI study.

Authors:  Jorge Cabello; Mihai Avram; Felix Brandl; Mona Mustafa; Martin Scherr; Claudia Leucht; Stefan Leucht; Christian Sorg; Sibylle I Ziegler
Journal:  EJNMMI Res       Date:  2019-08-19       Impact factor: 3.138

9.  Single cocaine exposure does not alter striatal pre-synaptic dopamine function in mice: an [18 F]-FDOPA PET study.

Authors:  David R Bonsall; Michelle Kokkinou; Mattia Veronese; Christopher Coello; Lisa A Wells; Oliver D Howes
Journal:  J Neurochem       Date:  2017-10-26       Impact factor: 5.372

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.